The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
Open accessAbstract
BACKGROUND: Cytomegalovirus (CMV) infection is a leading cause of illness and death in patients who have undergone allogeneic hematopoietic-cell transplantation. Available treatments are restricted by clinically significant toxic effects and drug resistance. METHODS: In this phase 2 study, we evaluated the effect of letermovir (also known as AIC246), a new anti-CMV drug with a novel mechanism of action, on the incidence and time to onset of prophylaxis failure in CMV-seropositive recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donors. From March 2010 through October 2011, we randomly assigned 131 transplant recipients in a 3:1 ratio to three sequential study cohorts according to a double-blind design. Patients received oral letermovir (at a dose of 60, 120, or 240 mg per day, or matching placebo) for 12 weeks after engraftment. The primary end point was all-cause prophylaxis failure, defined as discontinuation of the study drug because of CMV antigen or DNA detection, end-organ disease, or any other cause. Patients underwent weekly surveillance for CMV infection. RESULTS: The reduction in the incidence of all-cause prophylaxis failure was dose-dependent. The incidence of prophylaxis failure with letermovir, as compared with placebo, was 48% versus 64% at a daily letermovir dose of 60 mg (P=0.32), 32% at a dose of 120 mg (P=0.01), and 29% at a dose of 240 mg (P=0.007). Kaplan-Meier time-to-onset profiles for prophylaxis failure showed a significant difference in the comparison of letermovir at a dose of 240 mg per day with placebo (P=0.002). The safety profile of letermovir was similar to placebo, with no indication of hematologic toxicity or nephrotoxicity. CONCLUSIONS: Letermovir, as compared with placebo, was effective in reducing the incidence of CMV infection in recipients of allogeneic hematopoietic-cell transplants. The highest dose (240 mg per day) had the greatest anti-CMV activity, with an acceptable safety profile. (Funded by AiCuris; ClinicalTrials.gov number, NCT01063829.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
Ljungman, P., Griffiths, P., & Paya, C. (2002) · Clinical Infectious Diseases · doi:10.1086/339329 · Cited by 1,234
Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant
Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G., & Meyers†, J. D. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00003 · Cited by 650
Antiviral drugs for cytomegalovirus diseases
Biron, K. K. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.002 · Cited by 468
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Marty, F. M., Winston, D. J., Rowley, S. D., Vance, E., Papanicolaou, G. A., Mullane, K. M., Brundage, T. M., Robertson, A. T., Godkin, S., Momméja-Marin, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303688 · Cited by 374
Self-citationMarty, F. M., Ljungman, P., Papanicolaou, G. A., Winston, D. J., Chemaly, R. F., Strasfeld, L., Young, J.-A. H., Rodriguez, T., Maertens, J., Schmitt, M., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70024-x · Cited by 350
Self-citationGoldner, T., Hewlett, G., Ettischer, N., Ruebsamen‐Schaeff, H., Zimmermann, H., & Lischka, P. (2011) · Journal of Virology · doi:10.1128/jvi.05265-11 · Cited by 336
Self-citationWinston, D. J., Young, J.-A. H., Pullarkat, V., Papanicolaou, G. A., Vij, R., Vance, E., Alangaden, G. J., Chemaly, R. F., Petersen, F., Chao, N., et al. (2008) · Blood · doi:10.1182/blood-2007-11-121558 · Cited by 245
Self-citationIn Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246
Lischka, P., Hewlett, G., Wunberg, T., Baumeister, J., Paulsen, D., Goldner, T., Ruebsamen-Schaeff, H., & Zimmermann, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01596-09 · Cited by 240
Self-citationCytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
Ljungman, P., Hakki, M., & Boeckh, M. (2010) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.01.008 · Cited by 160
Marschall, M., Stamminger, T., Urban, A., Wildum, S., Ruebsamen‐Schaeff, H., Zimmermann, H., & Lischka, P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05908-11 · Cited by 120
Self-citationComplications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future
Boeckh, M. (2011) · Hematology · doi:10.1182/asheducation-2011.1.305 · Cited by 92
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M., Ljungman, P., Chemaly, R. F., Maertens, J., Dadwal, S. S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706640 · Cited by 1,238
Self-citationKotton, C. N., Kumar, D., Caliendo, A. M., Huprikar, S., Chou, S., Danziger-Isakov, L., & Humar, A. (2018) · Transplantation · doi:10.1097/tp.0000000000002191 · Cited by 1,152
Ljungman, P., Boeckh, M., Hirsch, H. H., Josephson, F., Lundgren, J., Nichols, G., Pikis, A., Razonable, R. R., Miller, V., & Griffiths, P. D. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw668 · Cited by 955
Pathogenesis of human cytomegalovirus in the immunocompromised host
Griffiths, P., & Reeves, M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00582-z · Cited by 610
Metadata
- Authors
- Chemaly, R. F., Ullmann, A. J., Stoelben, S., Richard, M. P., Bornhäuser, M., Groth, C., Einsele, H., Silverman, M., Mullane, K. M., Brown, J., Nowak, H., Kölling, K., Stobernack, H. P., Lischka, P., Zimmermann, H., Rübsamen-Schaeff, H., Champlin, R. E., & Ehninger, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-08
- Volume
- 370
- Issue
- 19
- Pages
- 1781-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046433603
- Cited by
- 378
- References
- 11
- FWCI
- 31.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.